genome editing Market

The genome editing market is projected to reach US$ 16,986.69 million by 2028 from US$ 5,199.40 million in 2021; it is expected to grow at a CAGR of 18.4% from 2021 to 2028.

The constant advancements in genome editing technologies have been making headlines in recent years. These technologies have the potential to transform biological research and have far-reaching impacts on human health, food security, and the environment due to their precision, affordability, ease of use, and power. The origins of genome editing can be traced back to the 1990s, but it wasn't until the introduction of CRISPR-Cas9, a simple and targeted genome-editing tool, that the use and scope of these technologies expanded. CRISPR's ease of use compared to previous methods has led to its widespread adoption. As a result, genome editing has the potential to drive sustainable development, environmental management, food security, and the development of affordable diagnostics and treatments for various diseases.

Researchers from MIT and Harvard's Broad Institute have developed a new CRISPR genome-editing technique that has the potential to correct up to 89% of genetic abnormalities causing diseases. The team merged two major proteins in molecular biology, CRISPR-Cas9 and reverse transcriptase, into one machine. The resulting method, called prime editing, can precisely and efficiently alter human cells in a highly versatile manner. The team also turned a CRISPR RNA-cutting enzyme into an antiviral agent that can detect and eliminate RNA-based viruses in human cells. This is a primary study to use Cas13, or any CRISPR system, as an antiviral in human cells in culture. Cas13 has previously been used to alter human RNA and as a diagnostic tool for detecting the presence of viruses, bacteria, and other targets.

The Government of India's Department of Biotechnology (DBT) has been encouraging research and innovation in genome engineering techniques and their applications in order to make them more affordable and accessible for R&D. This has been done through specific initiatives, such as developing new methods, tools, processes, and platforms for genome editing, refining existing genome-editing methods, and applying genome editing technologies to agriculture, bioenergy, environmental research, and human health.

When preparing a report about the genome editing market, the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Health and Wellness Centers for Medicare and Medicaid Services (CMS), and Federal Trade Commission (FTC) are cited as primary and secondary sources of information.